pubmed.ncbi.nlm.nih.gov

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition - PubMed

️Sat Jan 01 2005

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

Shi-Yong Sun et al. Cancer Res. 2005.

Abstract

The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Rapamycin and its derivatives that specifically inhibit mTOR are now being actively evaluated in clinical trials. Recently, the inhibition of mTOR has been shown to reverse Akt-dependent prostate intraepithelial neoplasia. However, many cancer cells are resistant to rapamycin and its derivatives. The mechanism of this resistance remains a subject of major therapeutic significance. Here we report that the inhibition of mTOR by rapamycin triggers the activation of two survival signaling pathways that may contribute to drug resistance. Treatment of human lung cancer cells with rapamycin suppressed the phosphorylation of p70S6 kinase and 4E-BP1, indicating an inhibition of mTOR signaling. Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E. The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process. The activated Akt and eIF4E seem to attenuate rapamycin's growth-inhibitory effects, serving as a negative feedback mechanism. In support of this model, rapamycin combined with LY294002 exhibited enhanced inhibitory effects on the growth and colony formation of cancer cells. Thus, our study provides a mechanistic basis for enhancing mTOR-targeted cancer therapy by combining an mTOR inhibitor with a PI3K or Akt inhibitor.

PubMed Disclaimer

Cited by

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M. Soler A, et al. Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. doi: 10.1158/1078-0432.CCR-15-3051. Epub 2016 May 25. Clin Cancer Res. 2016. PMID: 27225693 Free PMC article.
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition.
Smith KB, Tran LM, Tam BM, Shurell EM, Li Y, Braas D, Tap WD, Christofk HR, Dry SM, Eilber FC, Wu H. Smith KB, et al. Am J Pathol. 2013 Apr;182(4):1400-11. doi: 10.1016/j.ajpath.2013.01.002. Epub 2013 Feb 12. Am J Pathol. 2013. PMID: 23416162 Free PMC article.
Inhibition of protein synthesis alters protein degradation through activation of protein kinase B (AKT).
Dai CL, Shi J, Chen Y, Iqbal K, Liu F, Gong CX. Dai CL, et al. J Biol Chem. 2013 Aug 16;288(33):23875-83. doi: 10.1074/jbc.M112.445148. Epub 2013 Jul 10. J Biol Chem. 2013. PMID: 23843462 Free PMC article.
Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M, Grottke A, Mueck K, Manes J, Jücker M, Rodemann HP, Toulany M. Holler M, et al. PLoS One. 2016 May 3;11(5):e0154745. doi: 10.1371/journal.pone.0154745. eCollection 2016. PLoS One. 2016. PMID: 27137757 Free PMC article.
Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Fan QW, Weiss WA. Fan QW, et al. Methods Mol Biol. 2012;821:349-59. doi: 10.1007/978-1-61779-430-8_22. Methods Mol Biol. 2012. PMID: 22125077 Free PMC article.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition - PubMed